Spiolto ® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist; Drug: Tripple combination of Free or fixed Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist Sponsor: Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials